Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929444 | 0.98 | HDAC3 (0.50) | FOLH1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL929642 | 0.92 | — | — | |
| SCHEMBL929190 | 0.83 | HDAC3 (0.58) | FOLH1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL24855609 | 0.83 | HDAC3 (0.49) | FOLH1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28753535 | 0.82 | FAAH (0.50) | FAAH | |
| SCHEMBL930337 | 0.81 | — | — | |
| SCHEMBL4345946 | 0.81 | HDAC3 (0.59) | FOLH1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL15452323 | 0.79 | FAAH (0.69) | FOLH1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL15452322 | 0.79 | FAAH (0.69) | FOLH1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL21307961 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | claimed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | claimed |
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | disclosed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | KRT18, CKAP4, S100A4 | FOLH1 499/4885HDAC3 490/4885HDAC1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.